A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Inclusion criteria:

Pooled OMB and OCR Cohorts:

• ≥1 incident claim for OMB (Pooled OMB Cohort) or OCR (Pooled OCR Cohort) in the patient identification period (index date = first claim date).
• No claims for OMB or OCR within the 12 months prior to the index date.
• ≥2 outpatient (OP) medical claims (at least 30 days apart) with a diagnosis code for MS (International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] code: G35) in any position, with the first claim occurring in the 12 months prior to or on index date and the second claim up to 6 months after index date, or ≥1 inpatient (IP) claim with a diagnosis of MS in the first position in the 12 months prior to or on index date.
• ≥18 years of age on index date.
• Continuous healthcare plan enrollment for ≥12 months prior to index date (baseline period) and ≥6 months after index date (follow-up period).
• Persistent use of OMB (Pooled OMB Cohort) or OCR (Pooled OCR Cohort) for ≥6 months after index date.

Treatment-naïve OMB and OCR Cohorts:

• Included in Pooled OMB Cohort or Pooled OCR Cohort.
• No claims for a disease modifying therapy (DMT) used for the treatment of MS within the 12-month baseline period.

Exclusion criteria:

• None.